



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/28 (2006.01)

A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2022/035220

(22) International Filing Date:

28 June 2022 (28.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/216,233 29 June 2021 (29.06.2021) US

63/318,920 11 March 2022 (11.03.2022) US

(71) Applicant: SEAGEN INC. [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(72) Inventors: DIOLAITI, Daniel; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). GARDAI, Shyra; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US).


(74) Agent: BANKO, Max et al.; Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF TREATING CANCER WITH A COMBINATION OF A NONFUCOSYLATED ANTI-CD70 ANTIBODY AND A CD47 ANTAGONIST

FIG. 1



(57) Abstract: The invention provides methods of treating cancer, such as myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with a nonfucosylated anti-CD70 antibody in combination with a CD47 antagonist.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*